Neurocrine Biosciences leads structurally, with growth as the clearest single gap between the two profiles. Genmab A/S still has the edge on profitability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.
The comparison is based on similar long-term financial trajectories, not sector labels.
The comparison is mainly decided in growth, with the rest of the profile carrying less weight. Neurocrine Biosciences, Inc. leads by 11 points on the overall comparison score.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.
The strongest overlap appears in investment intensity and recent revenue growth.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in growth.
Left means cheaper relative valuation. Higher means stronger structure.
Neurocrine Biosciences, Inc. occupies the cheaper side of the setup map, although Genmab A/S still holds the stronger structural profile.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Revenue growth reinforces the category-level growth lead.
Neurocrine Biosciences, Inc. also looks less cycle-sensitive, which gives the profile a calmer footing than a pure score split would imply.
Growth settles the comparison, while pricing and profitability keep the broader setup from looking fully aligned.
Break down the GMAB.CO vs NBIX comparison across all dimensions with the full interactive tool.
Explore how GMAB.CO and NBIX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.